Mostafa Faisal: Romiplostim Shows Safety and Efficacy in Pediatric Post-HSCT Thrombocytopenia

Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared a post on X about a recent article by Zahra Karimizadeh et al, published in Transplantation and Cellular Therapy:

“Efficacy and Safety of Romiplostim in Treating Thrombocytopenia After Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial

1. Pediatric post-HSCT thrombocytopenia
   Prospective trial • 47 pts • median age 7 yrs
2. Romiplostim 5 μg/kg weekly (PIT n=14 • SFPR n=33)
3. ORR 80.9% CR 42.6% • PR 25.5% • MR 12.8%
4. Platelets >50×10⁹/L in 3 weeks
   82% maintained response off-treatment ≥12 weeks
5. Platelet transfusion independence 74.5%
   RBC independence 78.9%
   Bleeding grade 0–1 increased to 80.9%
6. Erythroid response 81.6%
   Neutrophil improvement 50%
7. No serious AEs • minor AEs 27.7% GVHD: acute 53% (III–IV 36%) • chronic 25.5%”

Title: Efficacy and Safety of Romiplostim in Treating Thrombocytopenia After Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial

Authors: Zahra Karimizadeh, Maryam Behfar, Atieh Karimzadeh, Leila Jafari, Amirali Kalantari, Zeynab Nikfetrat, Amir Ali Hamidieh

Read the Full Article on Transplantation and Cellular Therapy

More posts featuring Mostafa Faisal.